Histopathological analysis of T1 renal cell carcinoma: Does presentation matter?

Gaurav Gupta, Samiran Das Adhikary, Santosh Kumar, Ninan K. Chacko, Nitin S. Kekre, Ganesh Gopalakrishnan
Department of Urology, Christian Medical College and Hospital, Vellore, Tamil Nadu - 632 004, India

ABSTRACT

Objectives: To study the differences in the clinico-pathological features of incidental and symptomatic T1 renal cell carcinoma (RCC) and to see, particularly in T1b RCC, if symptomatic presentation has adverse pathological features concerning the oncological safety of elective nephron-sparing surgery (NSS) in this subgroup.

Materials and Methods: Of 278 patients who underwent radical nephrectomy for RCC from January 1995 to January 2005, 70 had tumor size up to 7 cm (T1). They were categorized as incidental or symptomatic and as T1a or T1b tumors. Clinico-pathological features were compared between incidental (IRCC) and symptomatic (SRCC) groups. Tumors were analyzed using the 1997 TNM staging and Fuhrman’s grade.

Results: Of the 70 with T1 tumors, 24 had T1a (IRCC, 12 and SRCC, 12) and 46 had T1b tumors (IRCC, 27 and SRCC, 19). Clear cell was the commonest histology. In T1a cancers, though no significant difference in histopathological pattern and grade was seen between the incidental and symptomatic groups, symptomatic tumors had more papillary, mixed histopathological pattern and higher nuclear grade. Among T1b tumors, 14 had papillary and mixed histology, 12 (86%) of which were symptomatic ($P<0.0001$). In T1b, 15 (79%) symptomatic had higher nuclear grade (G2-3) while 22 (81%) incidental had lower Fuhrman’s grade ($P<0.0001$).

Conclusion: Symptomatic T1b RCCs had higher nuclear grade and papillary histology. This difference was statistically significant. This may be relevant when considering elective NSS in symptomatic T1b disease.

Key words: Incidental, nephron-sparing surgery, renal cell carcinoma

INTRODUCTION

Renal cell carcinoma (RCC) accounts for approximately 2% of adult malignancies and 80-85% of malignant kidney tumors.[1] With the increasing use of noninvasive imaging in those with nonspecific symptoms, more than 50% of the RCCs are detected incidentally in younger age and are now referred to as the “radiologist’s tumor”. [1,2]

Studies have demonstrated that incidental RCCs tend to be smaller, lower-stage and with better survival outcomes as compared to symptomatic RCC. [3] Although the contributions of lead and length time bias have not been defined, others have challenged this claim. [4,5]

With the evolution of nephron-sparing surgery (NSS), open or laparoscopic partial nephrectomy has become the standard of care. While absolute indications for NSS are well accepted, the most controversial in current practice are the elective indications. Based on existing data, elective partial nephrectomy is usually indicated for a renal mass less than 4 cm in size, peripherally located and easily resectable. [6-8] Recently, several investigators have questioned the conventional 4 cm size cutoff for elective partial nephrectomy [9] and have extended its application to T1b tumors.

While studying T1 RCC we were surprised at some features of its clinico-pathological profile. This has made us raise concerns about the oncological safety of NSS in T1b cancers.

MATERIALS AND METHODS

This retrospective review was conducted from January 1995 to January 2005. Of 278 patients who underwent radical nephrectomy, 70 (25%) with T1 stage formed the study group. Those with familial and bilateral RCCs were excluded.
from the study. Patients were categorized according to their clinical presentation. Tumors diagnosed incidentally as a part of a health checkup or for evaluation of vague upper gastrointestinal symptoms comprised the incidental (IRCC) group. Patients presenting with loin pain, hematuria, weight loss, cachexia and mass formed the symptomatic (SRCC) group. Of the 70 patients, 39 (56%) and 31 (44%) were in IRCC and SRCC groups respectively.

The histopathological data was retrieved from the pathology database. Staging was based on TNM, 1997 classification. For grading Fuhrman nuclear grade was used. Both groups were compared for clinical and pathological parameters with mean follow-up of 36 (12-108) and 60 (12-120) months in IRCC and SRCC groups respectively.

Statistical analysis
All the categorical variables were summarized using frequencies and percentages. Significance was calculated using Fisher’s exact test. A two tailed P-value < 0.05 was considered as statistically significant.

RESULTS

Patient characteristics
The mean age in the IRCC and SRCC group was 52.6 (32-76 years) and 52.4 (21-76 years) years respectively. Female preponderance was seen in incidentally detected RCC (46%), as compared to the symptomatic group (16%). In the symptomatic group the majority presented with hematuria [Table 1].

Tumor characteristics
Patient distribution in IRCC and SRCC is shown in Table 2. Pathological examination of operative specimen of $T_{1a}$ group did not reveal a statistical difference for different histological patterns (clear cell vs. papillary and mixed; $P=0.37$) and grade (Grade-1 vs. Grade 2-3; $P=0.09$). In the $T_{1b}$ group, compared to the clear cell type, papillary and mixed histological varieties were significantly more in the SRCC than IRCC group ($P<0.0001$). Symptomatic $T_{1b}$ RCCs had a significantly higher grade (2-3) [Table 3] than Grade-1 ($P<0.0001$).

One of the patients in SRCC $T_{1b}$ had sarcomatoid variant of clear cell type. One in $T_{1a}$ SRCC (8%) and two in SRCC $T_{1b}$ (11%) group developed distant metastasis at 64, 34 and 48 months of follow-up respectively but none developed in the IRCC group. In SRCC $T_{1a}$ and $T_{1b}$ the five-year cancer-specific survival rate was 100 and 89%. While in IRCC $T_{1a}$ and $T_{1b}$ it was 100%. The mean follow-up in IRCC and SRCC was 36 (12-108) and 60 months (12-120 months) respectively.

DISCUSSION

Renal cell carcinoma is characterized by diverse clinical manifestations. Small, localized tumors rarely produce symptoms and for this reason the diagnosis is often delayed. Symptomatic presentation is usually a sign of advanced disease. The most common presentations are hematuria (50-60%), abdominal pain (40%), and a palpable mass in the flank or abdomen (30-40%). These three symptoms occur as a combination (“classic triad”) in less than 10% of patients. Other signs and symptoms are relatively nonspecific — fever, night sweats, malaise, and weight loss. In our series hematuria was the most common presentation, which is intuitively a sign of pelvi-calyceal system invasion and makes metastasis disease more possible. Several studies have demonstrated that incidental neoplasms tend to be smaller, lower stage and grade and have better survival outcomes when compared with symptomatic RCC.[3] On analyzing our results we also found that incidental tumors were low-grade and with a favorable histology as compared to the symptomatic tumors. Licht et al., found that symptomatic renal tumors (>4 cm) treated with partial nephrectomy had a statistically significant worse prognosis. In their series five-year cancer-specific survival rates for incidental and symptomatic RCC was 94 and 83%.[11] This prompted Patard et al., to propose a classification based on mode of presentation (incidental or symptomatic) combined with tumor size to stratify prognosis.[12]

Renshaw et al., found that papillary RCCs were more aggressive as compared to clear cell RCC. In $T_{1a}$, seven patients had papillary and mixed histology, of which five were symptomatic. In $T_{1b}$ papillary and mixed histology was seen in 14 patients, of which 12 were symptomatic ($P=0.0001$; Table 3). Kletscher et al., have shown that multi-focality occur at a significantly higher rate ($P=0.011$) with papillary and mixed histological pattern.[14] Sarcomatoid histology is no longer considered a distinct subtype of RCC. It represents a relatively rare, poorly differentiated form of RCC subtypes; seen in less than 5% of RCCs and associated with dismal prognosis.[15] In our study sarcomatoid differentiation was seen in one patient who had a symptomatic presentation.

### Table 1: Presentation in SRCC group (n=31)

| Symptom          | No (%) |
|------------------|--------|
| Hematuria        | 28 (90) |
| Mass             | 01 (03) |
| Pain             | 12 (39) |
| Weight loss      | 08 (26) |

### Table 2: T1 stage and sub-classification of IRCC and SRCC

| Stage    | IRCC, no (%) | SRCC, no (%) |
|----------|--------------|--------------|
| T1       | 39 (56)      | 31 (44)      |
| $T_{1a}$ (<4cm) | 12 (50)      | 12 (50)      |
| $T_{1b}$ (>4-7cm) | 27 (59)      | 19 (41)      |
Ghavamian et al., in a multivariate model reported, tumor stage and nuclear grade were significantly associated with death from RCC.[16] Castilla et al., reported significant risk of disease progression with increasing Fuhrman nuclear grade. [17] In Fuhrman’s original report, the five-year survival rates for Grades 1 to 4 were 64%, 34%, 31% and 10% respectively. Nuclear grade proved to be the most significant prognostic factor for Stage-I tumor in his series. [18] In our study, 15 in the SRCC group as compared to 5 in the IRCC of the T1b had higher nuclear grade (G2,3) [Table 3]. Fergany et al., have shown a significant survival benefit not only for smaller lesions but also for those who had incidental presentation and with lower grade.[6]

Elective NSS has become standard treatment for T1a tumors. The rate of local recurrence in partial nephrectomy varies from 0–10%[19] and reflects the fact that most patients treated in this manner had large tumors, multi-focal tumors (microscopic/macroscopic), or both. Reported overall survival of NSS is similar to that of patients with disease of similar stage (T1) when compared with radical nephrectomy. [6,8] In the era of advanced laparoscopic surgery technical success is excellent and operative morbidity and mortalities are low.[19] In contemporary series cancer-specific survival has been found to be between 95–100%,[19] Because of these favorable results in T1a RCCs and increased number of diagnosis at early stage of tumors, elective NSS approach has been extended to select exophytic >4-7 cm size RCCs be they symptomatic or incidental. This is in spite of large partial nephrectomy series, showing size to be the most significant predictor of cancer-related outcome [Table 3].[6,7,9,11]

Rational for expanding elective NSS to larger tumors include recent changes in the staging of RCC suggesting a favorable tumor-related prognosis for individuals with tumors less than 7 cm, increase in the life expectancy, incidental diagnosis at an earlier age and metachronous tumor recurrences in patients undergoing radical nephrectomy and thus increased concerns about the long-term risk of renal insufficiency. Our analysis on tumors > 4 cm in size has shown that symptomatic RCCs were associated with higher nuclear grade and papillary histology; the latter is associated with multi-centricity and could account for lower disease-free survival in T1b RCCs as reported in the literature. This data indicates that it may be a cause for concern for elective NSS in those who had symptomatic presentation.

In this context we feel that there could be a role of core needle biopsy in the management decision for symptomatic T1b RCC. In a review by Lane et al., renal mass biopsy has a 94% overall accuracy for identifying RCC subtypes.[20] Fuhrman nuclear grade has been assessed correctly up to 83% on these biopsies. These discrepancies in grades are likely due to tumor heterogeneity, since 16-25% of renal tumors show some variability of grade.[21] Hence to enhance the yield, it is important to obtain samples from various areas of the mass. [20] In conjunction with conventional histological analysis of renal mass biopsies, using core needle biopsy (18-gauge needle) with minimal or no increase in risk of complications, [20] additional tests such as immunohistochemistry, molecular markers, fluorescent in-situ hybridization[22] and polymerase chain reaction[23] further improve the accuracy of these biopsies.

This is a retrospective analysis with small numbers. Further

---

**Table 3: Histopathological characteristics in Incidental and Symptomatic renal cell carcinoma**

|                      | T1a (n=24) | T1b (n=46) |
|----------------------|------------|------------|
|                      | IRCC (n=12) | SRCC (n=12) | P    | IRCC (n=27) | SRCC (n=19) | P      |
| Clear cell (%)       | 10 (59%)   | 07 (41%)   | 0.37 | 25 (78%)   | 07 (22%)   | 0.0001 |
| Papillary (%)        | 01 (25%)   | 02 (66%)   |      | 02 (17%)   | 02 (100%)  |        |
| Mixed (%)            | 01 (33%)   | 02 (66%)   |      | 00 (0%)    | 02 (100%)  |        |
| Grade-1 (%)          | 09 (75%)   | 04 (25%)   |      | 22 (85%)   | 04 (15%)   |        |
| Grade-2 (%)          | 03 (30%)   | 06 (70%)   | 0.09 | 04 (29%)   | 10 (71%)   | 0.0001 |
| Grade-3 (%)          | 00 (0%)    | 02 (100%)  |      | 01 (17%)   | 05 (83%)   |        |
| Mean tumor size      | 3.5 (3.5-4)| 3.7 (3-4)  | n.s. | 5.6 (4.5-7)| 5.5 (5-7)  | n.s.   |

Size in cm (range), n.s.: not significant

---

**Table 4: Disease-free survival in patients after NSS evaluated by tumor size**

| Study                  | Total No. of patients | Number <4 / 4-7 cm | Five-year cancer-specific survival (%) | Electively done (%) |
|------------------------|-----------------------|--------------------|---------------------------------------|---------------------|
|                        |                       |                    | <4cm                                  | 4-7cm               | done (%) |
| Fergany et al.[6]      | 107                   | 43 / 21            |                                       |                     | 98       | 95     | 02     |
| Hafez et al.[7]        | 485                   | 240 / 80           |                                       |                     | 96       | 86     | 09     |
| Belldegrun et al.[9]   | 108                   | 53 / 10            |                                       |                     | 100      | 90     | 58     |
| Lich et al.[11]        | 216                   | 124 / 82           |                                       |                     | 97       | 79     | 08     |

---
prospective studies are required to analyze the adverse factors of elective NSS in symptomatic T1b RCCs.

CONCLUSION

Symptomatic RCCs had a higher nuclear grade and unfavorable histology. In partial nephrectomy the main worry is of local tumor recurrence and metastasis thus affecting the disease-free survival. We have found that symptomatic T1b RCC had an unfavorable histology and higher grade both of which are known to be associated with multi-centricity, higher recurrence rate and poor prognosis. These data indicate that NSS should be avoided in symptomatic RCCs but could be extended to select incidentally diagnosed 4-7cm-sized renal cell carcinomas.

REFERENCES

1. Motzer RJ, Bancer NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996;335:865-75.
2. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology 2000;56:58-62.
3. Konnak JW, Grossman HB. Renal cell carcinoma as an incidental finding. J Urol 1985;134:1094-6.
4. Rodriguez-Rubio FI, Diez-Caballero F, Martin-Marquina A, Abad JI, Berian JM. Incidentally detected renal cell carcinoma. Br J Urol 1996;78:29-32.
5. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998;5:203-5.
6. Fargany AF, Hafez KS, Novic AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10 year follow-up. J Urol 2000;163:442-5.
7. Hafez KS, Fargany AF, Novic AC. Nephron sparing surgery for localized renal cell carcinoma: Impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999;162:1930-3.
8. Lau WK, Blute ML, Weaver AL. Matched comparison of radical nephrectomy vs nephron sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75:1236-42.
9. Beldegrun A, Tusi KH, deKernion JB. Efficacy of nephrectomy using nephron sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol 1999;17:2868-75.
10. Porena M, Vespasiani G, Rosi P. Incidentally detected renal cell carcinoma: role of ultrasonography. J Clin Ultrasound 1992;20:395-400.
11. Licht MR, Novick AC, Goormastic M. Nephron sparing surgery in incidental versus suspected renal cell carcinoma. J Urol 1994;152:39-42.
12. Patard JJ, Dorey FJ, Clindolo L. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol 2004;172:167-71.
13. Renshaw AA, Richie JP. Subtypes of renal cell carcinoma: Different onset and sites of metastatic disease. Am J Clin Pathol 1999;111:539-43.
14. Kletscher BA, Qian J, Bostwick DG. Prospective analysis of multifocality in renal cell carcinoma: Influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy. J Urol 1995;153:904-6.
15. Tomera KM, Farrow GM, Lieber MM. Sarcomatoid Renal carcinoma. J Urol 1983;130:657-9.
16. Ghavamian R, Cheville JC, Lohse CM. Renal cell carcinoma in the solitary kidney: An analysis of complications and outcome after nephron sparing surgery. J Urol 2002;168:454-9.
17. Castilla EA, Liou LS, Abrahams NA. Prognostic importance of resection margin width after nephron sparing surgery for renal cell carcinoma. Urology 2002;60:993-7.
18. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:355-63.
19. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indication, technique and outcomes. J Urol 2001;166:6-18.
20. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy: A renaissance? J Urol 2008;179:20-7.
21. Neuzillet Y, Lecavelier E, Andre M, Daniel L, Coulange C. Accuracy and clinical role of fine needle percutaneous biopsy with computer tomography guidance of small (less than 4.0 cm) renal masses. J Urol 2004;171:1802-5.
22. Barocas DA, Mathew S, Delpizzo JJ, Vaughan ED Jr, Sosa RE, Fine RG, et al. Renal cell carcinoma sub-typing by histopathology and fluorescence in situ hybridization on a needle biopsy specimen. BJU Int 2007;99:290-5.
23. Barocas DA, Rohan SM, Kao J, Gurevich RD, Del Pizzo JJ, Vaughan ED Jr, et al. Diagnosis of renal tumors on needle biopsy specimens by histological and molecular analysis. J Urol 2006;176:1957-62.

How to cite this article: Gupta G, Adhikary SD, Kumar S, Chacko NK, Kekre NS, Gopalakrishnan G. Histopathological analysis of T1 renal cell carcinoma: Does presentation matter?. Indian J Urol 2008;24:304-5.